A method for preventing radiation-induced ototoxicity in an individual in need thereof comprising intratympanic administration of a pharmaceutical composition comprising a therapeutic agent selected from a JNK inhibitor, TRPV modulator, an MET channel inhibitor, and an otoprotectant to the individual in need thereof, wherein the pharmaceutical composition is administered prior to onset of radiation therapy, and wherein the composition provides sustained release of the therapeutic agent into the ear for a period of at least 5 days after a single administration
Concentration and formulation considerations Higher concentration solutions generally absorb better because they maintain a stronger concentration gradient across the mucosal membrane
However, the black box warning regarding thyroid C-cell tumors observed in rodent studies necessitates careful patient selection and counseling, even though the relevance to human thyroid disease remains unclear
To our knowledge, no other clinical trials with IBD patients were performed
This peptide exists in two active forms, GLP-1(7-36) amide and GLP-1(7-37), both of which are functionally equivalent, although the former is more abundant (25-28)
Reduce pigmentation and dark spots
